Cytokine Release Syndrome Clinical Trial
Official title:
Cytokine With Jafron Haemoadsorption During Cardiopulmonary Bypass: Protocol for Randomized Controlled Report
Cardiopulmonary bypass (CPB) is often associated with degrees of complex inflammatory response mediated by various cytokines. This response can, in severe cases, lead to systemic hypotension and organ dysfunction. Cytokine removal might therefore improve outcomes of patients undergoing cardiac surgery. Jafron is a device designed to remove cytokine from the blood using haemoadsorption (HA). This preliminary report aims to evaluate the potential of Jafron to decrease peri-operative cytokine levels in cardiac surgery.
In this context the investigators introduce the study design for multi-centre pilot randomized report in 40 patients undergoing elective CPB procedures with an expected time >120 minutes for each extracorporeal procedure. Patients will be randomly allocated to either standard of care (n = 20) or Jafron HA(n = 20) during cardiopulmonary bypass (CPB). The primary outcome will be the difference between the two groups in cytokines levels (IL-2, IL-6,TNF-α, IFN gamma) and secondary parameters (Fibrinogen, Albumin, Platelets, Hemoglobin, Hematocrit, White Blood Cells, Neutrophils,Lymphocytes, Monocytes, Eosinophils, Basophils) will measured at anaesthesia induction, at the endof CPB , Primary outcomes: hemodynamics with or without vasoconstrictors use, the mechanical ventilation (MV) (hours) time and length of stay in intensive care unit (ICU) (hours). This prospectivemulti-centre randomized controlled report will take place in two Centres: Anthea Hospital, GVMCare & Research, Bari, Italy; Virgen de la Arrixaca University Hospital, Murcia, Spain; between May 2022 and September 2022. The target population per centre will include (n=20) patients; will beallocate for each center to either standard of care (n = 10) or Jafron HA (n = 10) planned for elective cardiac surgery with increased risk of cytokine release. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03685383 -
Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation
|
N/A | |
| Terminated |
NCT04540120 -
Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome
|
Phase 2 | |
| Terminated |
NCT03557749 -
Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies
|
||
| Active, not recruiting |
NCT04150913 -
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
|
Phase 2 | |
| Completed |
NCT04643678 -
Anakinra in the Management of COVID-19 Infection
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04975555 -
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
|
Phase 2 | |
| Terminated |
NCT04403685 -
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers
|
Phase 3 | |
| Completed |
NCT04366908 -
Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
|
Phase 2 | |
| Completed |
NCT04720378 -
Safety and Tolerability Study of IV ST266 in COVID-19 Subjects
|
Phase 1 | |
| Terminated |
NCT04415073 -
A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19
|
Phase 2 | |
| Completed |
NCT03533101 -
Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation
|
Phase 1/Phase 2 | |
| Completed |
NCT04403061 -
Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome
|
||
| Recruiting |
NCT05414162 -
Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy
|
||
| Completed |
NCT04475588 -
Efficacy and Safety of Itolizumab in COVID-19 Complications
|
Phase 2 | |
| Terminated |
NCT04377503 -
Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19
|
Phase 2 | |
| Recruiting |
NCT04781803 -
Cyclosporine on Day Zero as Prophylaxis for Cytokine Release Syndrome
|
Phase 2 | |
| Completed |
NCT01353157 -
Study of the Clinical Scoring System and Cytokines for Prediction of Inflammatory Response in Major Surgery
|
N/A | |
| Completed |
NCT04048525 -
Cytokine Removal With CVVHD Compared to CVVH
|
N/A | |
| Recruiting |
NCT04048434 -
Extracorporeal Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release Syndrome (CRS)
|
N/A | |
| Recruiting |
NCT04486521 -
Anti-IL6 and Corticosteroid Monotherapy vs Combination in COVID-19
|